Pharmaceuticals & Therapeutics

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

Darigold's partnership with Actus Nutrition isn't a retreat, but a strategic masterstroke redefining the value of milk in a high-tech protein market.

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

A new partnership is democratizing science for wellness brands, making it faster and cheaper to prove their final products work and earn customer trust.

As AI reshapes our world, Ishan Shivanand’s scientifically-backed meditation protocols are gaining traction. His new book just won a major award.

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

Amidst soaring HIV rates and public health emergencies, a new campaign shows why top-down solutions fail and community-led resilience is the only way forward.

A new study reveals molecular and AI-imaging tests provide distinct clues for Parkinson's, championing a dual-biomarker approach for earlier, more accurate diagnosis.

As climate volatility grows, insurers are turning to advanced analytics and open platforms to move from reactive payouts to proactive risk engineering.

Hannah Cranston Media's spot on Inc.'s Best Workplaces list is more than an HR win. It's a masterclass in turning employee-first policies into a powerful commercial advantage.

A heritage brand's new crackers reveal a masterclass in product innovation, using consumer data and strategic retail partnerships to conquer the snack aisle.

A new startup, morph, is embedding intelligence into materials themselves. This isn't just another app—it's a systemic shift rewriting the rules of industry.

With FDA backing for its novel drug HER-096, a Finnish biotech is advancing a therapy that could finally move beyond symptoms to modify Parkinson's progression.

China's CHANDO Group is turning Himalayan biodiversity and advanced R&D into a potent business strategy, setting a new benchmark for sustainable growth in beauty.

As Northstar Clean Technologies nears a key production milestone and expands to the U.S., its latest financials reveal a classic cleantech dilemma: a widening loss.

A novel drug for muscle loss in COPD patients has fully recruited its Phase 2 trial, a major step towards the first-ever treatment for sarcopenia.

New long-term data on pegcetacoplan offers significant hope for patients with rare, debilitating kidney diseases, strengthening Sobi's market position.

Haisco's Cipepofol gains US FDA approval, challenging Propofol with enhanced safety and signaling a new era of Chinese pharmaceutical innovation.